Associated Papers
A framework for the molecular identification of CHIP for clinical research.
Harraka P et al.
Hgg Advances, 2026
Inflammageing and clonal haematopoiesis interplay and their impact on human disease.
Hajishengallis G et al.
Nature Reviews. Molecular Cell Biology, 2026
Clonal hematopoiesis associates with prevalent and incident cardiometabolic disease in a cardiac catheterization cohort.
Regan JA et al.
Plos One, 2026
Smart Nonuniformity for Calibrating Sequencing Depth of a Targeted Gene Panel to Simultaneously Detect Somatic and Germline Variants.
O'Reilly RL et al.
The Journal of Molecular Diagnostics : Jmd, 2025
Clonal Hematopoiesis Associates with Prevalent and Incident Cardiometabolic Disease in High-Risk Individuals.
Regan JA et al.
Medrxiv : the Preprint Server for Health Sciences, 2025
Saliva-derived DNA is suitable for the detection of clonal haematopoiesis of indeterminate potential.
O'Reilly RL et al.
Scientific Reports, 2024
Human ASXL1-Mutant Hematopoiesis Is Driven by a Truncated Protein Associated with Aberrant Deubiquitination of H2AK119.
Köhnke T et al.
Blood Cancer Discovery, 2024
TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy.
Johnson WT et al.
Blood Advances, 2023
Leukocytes carrying Clonal Hematopoiesis of Indeterminate Potential (CHIP) Mutations invade Human Atherosclerotic Plaques.
von Scheidt M et al.
Medrxiv : the Preprint Server for Health Sciences, 2023
CNL and aCML should be considered as a single entity based on molecular profiles and outcomes.
Carreño-Tarragona G et al.
Blood Advances, 2023
The Impact of Inflammation-Induced Tumor Plasticity during Myeloid Transformation.
Yeaton A et al.
Cancer Discovery, 2022
Dangerous Liaisons between Tet2 Mutation, Inflammatory Monocytes, and Leukemogenesis.
Pietras EM et al.
Cancer Discovery, 2022
The longitudinal dynamics and natural history of clonal haematopoiesis.
Fabre MA et al.
Nature, 2022
TET2-Driven Clonal Hematopoiesis and Response to Canakinumab: An Exploratory Analysis of the CANTOS Randomized Clinical Trial.
Svensson EC et al.
Jama Cardiology, 2022
TET2 missense variants in human neoplasia. A proposal of structural and functional classification.
Bussaglia E et al.
Molecular Genetics & Genomic Medicine, 2019
Identification of Clonal Hematopoiesis Mutations in Solid Tumor Patients Undergoing Unpaired Next-Generation Sequencing Assays.
Coombs CC et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2018
The cysteine-rich domain of TET2 binds preferentially to mono- and dimethylated histone H3K36.
Yamagata K et al.
Journal of Biochemistry, 2017
Fumarate and Succinate Regulate Expression of Hypoxia-inducible Genes via TET Enzymes.
Laukka T et al.
The Journal of Biological Chemistry, 2016
Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas.
Palomero T et al.
Nature Genetics, 2014
Feature-based classification of amino acid substitutions outside conserved functional protein domains.
Gemovic B et al.
Thescientificworldjournal, 2013
The Interlaboratory RObustness of Next-generation sequencing (IRON) study: a deep sequencing investigation of TET2, CBL and KRAS mutations by an international consortium involving 10 laboratories.
Kohlmann A et al.
Leukemia, 2011
Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2.
Ko M et al.
Nature, 2010
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.
Abdel-Wahab O et al.
Blood, 2009
Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates.
Tefferi A et al.
Leukemia, 2009